Invention Grant
- Patent Title: Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same
-
Application No.: US16649225Application Date: 2018-09-21
-
Publication No.: US11447559B2Publication Date: 2022-09-20
- Inventor: Hye-Ji Choi , Jae-Chan Park , Hyung-Kwon Lim
- Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH , GREEN CROSS CORPORATION , DANA-FARBER CANCER INSTITUTE, INC.
- Applicant Address: KR Yongin-si; KR Yongin-si; US MA Boston
- Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH,GREEN CROSS CORPORATION,DANA-FARBER CANCER INSTITUTE, INC.
- Current Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH,GREEN CROSS CORPORATION,DANA-FARBER CANCER INSTITUTE, INC.
- Current Assignee Address: KR Yongin-si; KR Yongin-si; US MA Boston
- Agency: Sughrue Mion, PLLC
- Priority: KR10-2017-0127990 20170929
- International Application: PCT/KR2018/011318 WO 20180921
- International Announcement: WO2019/066435 WO 20190404
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; C12N15/63 ; A61K39/00
Abstract:
Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.
Public/Granted literature
Information query
